Since several receptor tyrosine kinases relevant to angiogenesis and homeostasis of TME are overexpressed predominantly due to inactivation of VHL gene in ccRCC, inhibitors targeted receptor tyrosine kinases such as sunitinib have become the one of first-line therapies for RCC treatment (101). Here, NTRK1 is linked to renal cell carcinoma.